Company news: Panacea Biotec
Panacea Biotec's oncology parenteral formulations facility at Baddi, Himachal Pradesh, has received United States Food & Drug Administration appro21-05-2019
21-05-2019
Panacea Biotec Ltd - 531349 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr. Rajesh Jain, Soshil Kumar Jain & Sandeep Jain21-05-2019
Panacea Biotec Ltd - 531349 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Compliance under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 In continuation to our letter dated May 20, 2019 intimating the date of proposed Board Meeting scheduled to be held on May 30, 2019, for approving the Audited Financial Results for the quarter/financial year ended 31st March, 2019 and pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith newspaper copies of the notice of Board Meeting published in the following newspapers on May 21, 2019:- Business Standard (English); Desh Sewak (Punjabi)21-05-2019
Panacea Biotec Ltd - 531349 - Panacea Biotec Receives Azacitidine USFDA Approval For US Market
This is to inform that Panacea Biotec''s Oncology Parenteral Formulation Facility at Baddi, Himachal Pradesh, India, received United States Food & Drug Administration (USFDA) approval for manufacture and supply of Azacitidine Injection, 100 mg/vial, for the US market. Panacea Biotec''s state-of-the-art pharmaceutical formulation facility at Baddi is already approved by National Regulatory Authority (NRA) of India and USFDA for other oral solids and injectable products.20-05-2019
Panacea Biotec Ltd - 531349 - Closure of Trading Window
In reference to our earlier announcement dated 29.03.2019 intimating the Closure of Trading Window pursuant to the Company's Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we would like to inform that the trading window of the Company shall remain closed for all Designated Persons of the Company and Material Subsidiaries of the Company till June 01, 2019 and the same will re-open from June 02, 2019.20-05-2019
PANACEA BIOTEC LTD. - 531349 - Board Meeting Intimation for For Approving The Audited Financial Results For The Quarter / Financial Year Ended March 31, 2019
PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2019 ,inter alia, to consider and approve the Audited Financial Results for the Quarter / Financial Year ended 31.03.2019. Further, pursuant to Regulations 46(2) & 47(1) of the SEBI LODR Regulations, notice of the said meeting is also being sent for publication in newspapers and uploaded on the website of the Company. Further, with reference to our earlier announcement dated 29.03.2019 intimating the Closure of Trading Window pursuant to the Company's Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we would like to inform that the trading window of the Company shall remain closed for all Designated Persons of the Company and Material Subsidiaries of the Company till June 01, 2019 and the same will re-open from June 02, 2019.20-05-2019
PANACEA BIOTEC LTD. - 531349 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SBICAP Trustee Company Ltd17-05-2019
Panacea Biotec Ltd - 531349 - Compliances-Certificate under Reg. 54 (5) of SEBI (DP) Regulations, 1996
Dear Sir, This is with reference to CDSL's Operating Instructions for Issuers/RTAs, which states that the Issuer/RTA shall inform the details of the securities dematerialized to all the Stock Exchanges where the securities are listed. Accordingly, we are enclosing herewith the data of shares dematerialized during the month of April, 2019.07-05-2019
PANACEA BIOTEC LTD. - 531349 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayPANACEA BIOTEC LTD. 2CININE922B01023 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 743 4Highest Credit Rating during the previous FY D 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Vinod Goel Designation: Group CFO and Head Legal & Company Secretary EmailId: companysec@panaceabiotec.com Name of the Chief Financial Officer: Devender Gupta Designation: Chief Financial Officer and Head IT EmailId: companysec@panaceabiotec.com Date: 30/04/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.30-04-2019
PANACEA BIOTEC LTD. - 531349 - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the revised disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr. Rajesh Jain & Others30-04-2019